United States · Bill · HR
H.R. 7537 (116th)
Infectious Disease Therapies Research and Innovation Act of 2020
Introduced
9 July 2020
Last action
—
Status
Referred to the House Committee on Ways and Means.
Sponsors
—
Subjects
Discovery layer
Source updated
3 January 2025
Summary
Infectious Disease Therapies Research and Innovation Act of 2020 This bill exempts from the definition of passive activity , for purposes of the passive loss tax rules, any qualified medical research activity of a specified medical research small business pass-thru entity. The bill defines specified medical research small business pass-thru entity as any domestic pass-thru entity if more than 80% of such entity's expenditures on research are paid or incurred in connection with qualified medical research activities and the gross receipts of such entity for the taxable year are less than $1 million.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in House (text)
Introduced in House (text)
Introduced in House · EN · 9 July 2020
Introduced in House (PDF)
Introduced in House · EN · 9 July 2020
Introduced in House
summary · EN · 9 July 2020
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/116th-congress/house-bill/7537
- Open data entity: https://api.congress.gov/v3/bill/116/hr/7537